These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6398966)

  • 1. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.
    Venditti JM; Wesley RA; Plowman J
    Adv Pharmacol Chemother; 1984; 20():1-20. PubMed ID: 6398966
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
    Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
    Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some thoughts on experimental models and their clinical correlations.
    Carter SK
    Eur J Cancer (1965); 1973; 9(11-12):833-41. PubMed ID: 4804310
    [No Abstract]   [Full Text] [Related]  

  • 4. Investigational drugs under study by the United States National Cancer Institute.
    Carter SK; Slavik M
    Cancer Treat Rev; 1976 Mar; 3(1):43-60. PubMed ID: 62615
    [No Abstract]   [Full Text] [Related]  

  • 5. [Psychotropic drugs and new 1,5-benzodiazepine analogs as antitumor agents].
    Werner W; Wohlrabe K; Gutsche W; Jungstand W; Römer W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(5):637-42. PubMed ID: 6172326
    [No Abstract]   [Full Text] [Related]  

  • 6. Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.
    Harrison SD; Plowman J; Dykes DJ; Waud WR; Griswold DP
    Cancer Chemother Pharmacol; 1990; 25(6):425-9. PubMed ID: 2311170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental antitumor activity of 5'-nor-anhydrovinblastine navelbine.
    Maral R; Bourut C; Chenu E; Mathé G
    Cancer Lett; 1984 Feb; 22(1):49-54. PubMed ID: 6697321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A.
    Rose WC; Schurig JE; Huftalen JB; Bradner WT
    Cancer Res; 1983 Apr; 43(4):1504-10. PubMed ID: 6831399
    [No Abstract]   [Full Text] [Related]  

  • 9. Antitumour activity of some cyclophosphazenes.
    Labarre JF; Faucher JP; Levy G; Sournies F; Cros S; François G
    Eur J Cancer (1965); 1979 May; 15(5):637-43. PubMed ID: 510331
    [No Abstract]   [Full Text] [Related]  

  • 10. In vivo antitumor evaluation of antibiotics. Selected results from the Drug Evaluation Program of the National Cancer Institute, U.S.A.
    Venditti JM; Johnson RK
    Recent Results Cancer Res; 1978; 63():49-57. PubMed ID: 705014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective screening program: current screening and its status.
    Goldin A; Venditti JM
    Recent Results Cancer Res; 1981; 76():176-91. PubMed ID: 7232850
    [No Abstract]   [Full Text] [Related]  

  • 12. [Models and methods used for the selection of antitumor preparations in the USSR and abroad].
    Sof'ina ZP
    Vopr Onkol; 1976; 22(4):82-96. PubMed ID: 1274284
    [No Abstract]   [Full Text] [Related]  

  • 13. Reversal of doxorubicin and cisplatin resistance in vivo in murine leukemias by the calcium antagonist RO 11-2933.
    Mazzoni A; Canti G
    Sel Cancer Ther; 1990; 6(4):167-76. PubMed ID: 2094936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumour activity of chlorimidazine on transplantable mouse tumour systems.
    Mircheva JJ; Pantev TP
    Chemotherapy; 1985; 31(6):472-5. PubMed ID: 4075859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI.
    Geran RI; Greenberg NH; Macdonald MM; Abbott BJ
    Natl Cancer Inst Monogr; 1977 Mar; (45):151-3. PubMed ID: 927490
    [No Abstract]   [Full Text] [Related]  

  • 16. Antitumor screening procedures of the National Cancer Institute.
    Schepartz SA
    Jpn J Antibiot; 1977 Dec; 30 Suppl():35-40. PubMed ID: 612710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The biochemical mechanisms of drug resistance to N-alkyl-N-nitrosoureas and derivatives of cis-dichlorodiammineplatinum].
    Gorbacheva LB
    Vopr Onkol; 1995; 41(2):50-1. PubMed ID: 7483435
    [No Abstract]   [Full Text] [Related]  

  • 18. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
    Fujimoto S; Ogawa M
    Cancer Chemother Pharmacol; 1982; 8(2):157-62. PubMed ID: 7105379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concepts for controlling drug-resistant tumor cells.
    Schabel FM; Skipper HE; Trader MW; Laster WR; Corbett TH; Griswold DP
    Eur J Cancer (1965); 1980; Suppl 1():199-211. PubMed ID: 6947891
    [No Abstract]   [Full Text] [Related]  

  • 20. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.